Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells $72,471.48 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,819 shares of Sight Sciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $2.92, for a total transaction of $72,471.48. Following the transaction, the chief executive officer now owns 5,676,331 shares in the company, valued at approximately $16,574,886.52. This trade represents a 0.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 2nd, Paul Badawi sold 12,236 shares of Sight Sciences stock. The stock was sold at an average price of $3.60, for a total transaction of $44,049.60.

Sight Sciences Trading Up 2.1 %

SGHT traded up $0.06 during trading on Tuesday, hitting $2.89. The company’s stock had a trading volume of 236,872 shares, compared to its average volume of 283,998. Sight Sciences, Inc. has a twelve month low of $2.67 and a twelve month high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The stock’s fifty day moving average price is $3.59 and its 200-day moving average price is $5.35. The firm has a market capitalization of $146.70 million, a P/E ratio of -2.83 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Sight Sciences

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in shares of Sight Sciences during the third quarter valued at about $75,000. Arkadios Wealth Advisors acquired a new position in shares of Sight Sciences during the fourth quarter worth approximately $47,000. The Manufacturers Life Insurance Company acquired a new position in shares of Sight Sciences during the second quarter worth approximately $95,000. GSA Capital Partners LLP acquired a new position in shares of Sight Sciences during the third quarter worth approximately $136,000. Finally, American Century Companies Inc. raised its position in shares of Sight Sciences by 31.1% during the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after purchasing an additional 8,527 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on SGHT. UBS Group began coverage on shares of Sight Sciences in a report on Friday, December 6th. They set a “buy” rating and a $5.50 price target on the stock. Citigroup cut their price objective on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Morgan Stanley cut their price objective on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, November 11th. Finally, Lake Street Capital dropped their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.72.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.